Financial Consulate’s Axsome Therapeutics AXSM Stock Holding History

Financial Consulate’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$196K	Sell	800 -417	-34%	-$90.4K	0.02%	155
2026 Q1	$206K	Hold	1,217	–	–	0.03%	149
2025 Q4	$222K	Hold	1,217	–	–	0.03%	155
2025 Q3	$148K	Buy	+1,217	New	+$137K	0.02%	187
2023 Q2	–	Sell	-5,220	Closed	-$322K	–	49
2023 Q1	$322K	Hold	5,220	–	–	0.11%	95
2022 Q4	$403K	Hold	5,220	–	–	0.14%	89
2022 Q3	$233K	Hold	5,220	–	–	0.1%	106
2022 Q2	$200K	Buy	5,220 +355	+7%	+$11.2K	0.09%	120
2022 Q1	$201K	Buy	+4,865	New	+$151K	0.08%	127

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Financial Consulate's AXSM Position: Q2 2026 in Review

Financial Consulate reduced its Axsome Therapeutics (AXSM) stake by 34% in Q2 2026, selling an estimated $90.4K and leaving 800 shares worth $196K. The position accounts for 0.02% of the portfolio, ranked #155.

Financial Consulate first reported a position in AXSM in Q1 2022 and has held it in 9 quarters since. The position peaked at $403K in Q4 2022. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Financial Consulate held 800 shares of Axsome Therapeutics worth $196K as of Q2 2026.
Financial Consulate sold 417 Axsome Therapeutics shares in Q2 2026, an estimated $90.4K.
Axsome Therapeutics made up 0.02% of Financial Consulate's portfolio in Q2 2026, its #155 holding.
Financial Consulate first reported a position in Axsome Therapeutics in Q1 2022 and has held it in 9 quarters since.
Financial Consulate's Axsome Therapeutics position peaked at $403K in Q4 2022.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.